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Abstract 
In non-invasive anticancer photodynamic therapy (PDT), a nontoxic photosensitizer (PS), which is 
activated by visible light, is used as a magic bullet that selectively destroys cancer cells. Recently, we 
described the combined therapy of 5-aminolevulinic acid (ALA-PDT) with thiosemicarbazone 
(TSC), i.e. an iron-chelating agent. This resulted in a strong synergistic effect. Herein, we 
investigated a novel strategy using a combination of PDT consist of the xenobiotic-porphyrin type 
PS with TSC. We observed a synergistic effect for all of the pairs of TSC-PS. This approach can be 
rationalized by the fact that both chlorin and TSC can affect the generation of reactive oxygen 
species (ROS). In order to elucidate the plausible mechanism of action, we also combined the 
investigated PSs with DFO, which forms complexes that are redox inactive. We detected a slight 
antagonism or additivity for this combination. This may suggest that the ability of an iron chelator 
(IC) to participate in the production of ROS and the generation of oxidative stress is important. 
Key words: photodynamic therapy, thiosemicarbazone, photosensitizer, chlorin derivative, combination 
therapy, oxidative stress 
Introduction 
Thiosemicarbazones are a new class of 
compounds that have been suggested for anticancer 
therapy. These compounds bind metal ions and form 
active complexes. Their mechanism of action is 
multitargeted and consists of the deprivation of iron 
from cytosol, the generation of reactive oxygen 
species and the inhibition of the activity of 
ribonucleotide reductase [1]. Iron is a microelement 
that participates in a variety of important processes 
such as electron transport, DNA synthesis, oxygen 
delivery and erythropoiesis. One consequence of iron 
binding is the inhibition of the cell-division cycle and 
the arrest of cells at the G1/S interphase [2]. Depletion 
of iron also has an influence on the regulation of 
important genes (NDRG1 and BNIP3), which are 
crucial for triggering the apoptosis of cancer cells [3]. 
This multitargeted mechanism of action makes this 
type of compounds especially attractive material for 
the study of their possible application in anticancer 
therapy. The most popular derivative of this class of 
compounds is Triapine (3-AP) (Figure 1), which is a 
promising candidate for an anticancer drug. 
Currently, 3-AP is the first TSC ribonucleotide 
reductase inhibitor that has passed phase II of clinical 
trials [4]. Intensive research on the structure and 
activity of TSC has led to novel, highly active 
derivatives such as Dp44mT, which has been widely 
described in the literature [5,6]. More recently, TSC 
that are based on the 8-hydroxyquinoline moiety have 








compound MS168, which is a strong “booster” of 
protoporphyrin IX (PpIX), has been used in 
aminolevulinic acid-triggered photodynamic therapy 
[8]. Good results prompted us to try combination 
therapy with xenobiotic photosensitizers.  
Photodynamic therapy is a method of cancer 
treatment that is characterized by a high selectivity 
relative to normal cells. Both the specific structure of 
PS and the organization of the tumor tissue together 
contribute to the selectivity of PDT. The essence of 
this therapy is the production of singlet oxygen and 
free radicals in the reaction of PS with light of a 
suitable wavelength [9]. This energy changes the 
trigger chain reactions in the cell, thus causing various 
types of damage and finally the destruction of the 
tumor. The most commonly used PS are derivatives 
from the group of porphyrins, chlorins, 
phthalocyanines, naphthalocyanines or texaphyrins 
[10]. In comparison to porphyrins, chlorins have the 
maximum of fluorescence shifted towards longer 
wavelengths, which makes them more useful in 
therapy. For our research, we chose a recently 
published arabinose-based polyol derivative of 
chlorin (chlorin c), which has superior photophysical 
properties [11,12]. Moreover, the amphiphilic nature 
of this molecule guarantees good penetration through 
the cellular membrane and distribution via blood 
circulation. Foscan, a chlorin that is a drug approved 
for the PDT of the squamous cell carcinoma in Europe 
[13], was another PS that was tested in our study.  
Combination therapy is defined as the 
simultaneous use of more than one drug in order to 
achieve a therapeutic effect. When the total effect of a 
drug combination is greater than the sum of the 
effects that are triggered by the drugs individually, 
the interaction is synergistic [14]. However, the 
increase of activity is not the only benefit from the 
combination therapy of active substances. Dose 
reduction while maintaining effectiveness, the 
reduction of toxicity and an attack on several 
molecular targets simultaneously are some examples 
of the gains.  
As was mentioned above, we have recently 
shown that ALA-PDT can be efficiently boosted by 
the co-application of some redox-active TSCs, which 
may be explained by an increase in the formation of 
ROS. However, the mechanism of selective PpIX 
accumulation in a tumor is still not well understood. 
For example, the differences in iron metabolism and 
the expression of mitoferrins between a tumor and 
normal cells have recently been carefully investigated 
by Ogura et al. Those researchers found that the 
amount of mitochondrial labile iron ion and 
expression levels of mitochondrial iron transporters 
(mitoferrins) were lower in cancer cells than in normal 
cells [15]. Moreover, the metabolism of iron to heme is 
substantially lower in cancer cells. Consequently, the 
addition of sodium ferrous citrate as a source of iron 
resulted in lowering the accumulation of PpIX in both 
tumor and normal cells, but this level in cancer cells 
was still high enough to induce a therapeutic effect. 
This so-called Ogura effect is a good explanation for 
the remarkable selectivity of ALA-PDT. However, in 
the case of xenobiotic PS, the reverse effect was 
observed. Namely, the addition of iron during PDT 
treatment with phthalocyanines [16], chlorins [17,18] 
or porfimer [19] increased the effectivity of the 
therapy. This phenomenon may be connected with an 
increased ability to form 
ROS during an induced 
Fenton reaction. The 
addition of iron chelators 
such as DFO diminished 
cell death in PDT because 
DFO complexes with iron 
do not have redox potency 
[20,21]. In this regard, the 
interactions between iron 
chelators and exogenic PSs 
are particularly interesting.  
It is commonly 
known that the generation 
of ROS influences the 
cellular redox environment 
and leads to the induction 
of oxidative stress. There 
are many protective 
mechanisms in cells that 
destabilize radicals. The 
 
 
Fig. 1. Structures of TSCs (MS168, Dp44mT, 3-AP) and PSs (chlorin c, Foscan). 




most common are the genes that are responsible for 
the production of the proteins superoxide dismutase 
(MnSOD) and catalase (CAT). These two molecules 
are responsible for the degradation of superoxide and 
hydrogen peroxide, respectively. These genes are part 
of the natural defense of a cell, i.e. their antioxidant 
potential as well as their important, but still not clear 
role in diseases, have been reported [22]. Changes in 
the expression of such protective genes are a typical 
response in therapy with cytostatics or PDT [23,24]. 
Gołąb et al. showed that PDT induced the 
overexpression of MnSOD in cancer cells [25]. In 
colorectal cancer cells (HCT116) that are investigated 
in current study, the expression of MnSOD is strongly 
connected with activity of p53 [26]. The upregulation 
of MnSOD results in higher level of H2O2 generated in 
mitochondria and subsequent increase its 
concentration in cytosol, where it plays important role 
as signaling molecule. However this role is not yet 
fully understood, it has been proven to participate in 
cells proliferation activity in several cancers [27]. The 
vague function of MnSOD and H2O2 in cell is well 
illustrated by the changing classification of the 
dismutase encoding gene as tumor suppressor or 
oncogene [22]. In this regard the role of CAT as 
peroxide discharging protein become even more 
important. At lease in several cancers including 
prostate and colon cancer the ratio of MnSOD/CAT 
appeared to be crucial for cancer spread or treatment 
prognosis [28]. Moreover the catalase overexpression 
seems to induce better treatment sensitivity in cancer 
cells [29].  
 
Table 1. Calculated combination indexes for the combination of 
TSC and PS. 
CI[a]  chlorin c Foscan 
MS168 0.82±0.17  0.60±0.10 
Dp44mT 0.51±0.10  0.26±0.14  
3-AP 0.59±0.13  0.35±0.11 
DFO 1.13±0.20 1.05±0.19  
[a]for Fa=0.9, CI>1 – antagonism, CI=1 – additivity, CI<1 – synergy. Experiments 
were performed on the HCT116 cell line (see Supporting Information). 
 
Thus in our study we decided to investigate also 
the overall antioxidant response of the cell to 
combination therapy. For the similar mechanism of 
action of PDT and TSC drugs this may allow to clear 
out the intracellular mechanism laying beneath 
effectivity of phototherapy.  
Results and Discussion 
Among the factors that influence drug-drug 
interactions, the duration of an experiment and the 
concentrations applied play important, but unclear 
roles [14]. Thus, we decided to measure the cytotoxic 
effect after the simultaneous application of PS and 
TSC. An incubation of 48 h was selected as the optimal 
duration of the experiment. The cytotoxic effects were 
measured by determining the fraction of living cells 
by means of MTS assay. Concentrations of the tested 
compounds were selected based on IC50 (see SI Table 
S2). The interaction type and strength was assumed 
through a combination index (CI), which was 
calculated according to the useful method that was 
proposed by Chou [30]. As is summarized in Table 1, 
all of the CIs take a value < 1 for combinations with 
MS168, Dp44mT and 3-AP and >1 for DFO. 
Accordingly, we observed synergy for all of the 
combinations except DFO. The strongest synergy was 
observed for the combination of Dp44mT and Foscan 
(CI = 0.26), while the result for the combination of 
MS168 and chlorin c showed a considerably weaker 
interaction (CI=1 for the simple additivity). For DFO, 
we observed additivity/antagonism in combination 
with both of the PSs that were investigated. These 
results are particularly interesting as the tested PSs 
are exogenic compounds therefore, their 
concentration is independent of the iron level. 
Consequently, the mechanism of the interactions is 
different from the PpIX boosting that was 
demonstrated for ALA-PDT combined with an IC. We 
can hypothesize that both drugs interact 
complementarily via mechanisms that are based on 
oxidative stress. As was discussed in the introduction, 
TSCs generate reactive oxygen species in a Fenton 
reaction, thus leading to cellular damage [31]. At the 
same time, the absorption of energy by PSs results in a 
photodynamic reaction with oxygen, thereby 
producing more reactive singlet oxygen forms (1O2). 
Therefore, both PS and TSC produce ROS. It is well 
known that free radical reactions are very quick and 
cause damage that affects only a limited cellular area. 
Thus, the drug localization in a cell plays a crucial role 
for the efficiency of PDT [18,32]. As was highlighted 
above, for the phthalocyanine photosensitizer PC-4, 
the mitochondrial level of iron affected the overall 
effectivity of PDT in human head and neck carcinoma 
cells (UMSCC1) [16]. Therefore, in our experiments, 
we first verified the localization of the drugs that were 
being investigated. After incubation with the tested 
TSCs and PSs, the cells were stained with dyes that 
bind to mitochondria. The results of the experiments 
using a confocal microscope are shown in Figure 2. 
Analysis of the images indicated that all of the drugs 
were localized in mitochondria. Therefore, the 
observed co-localization may be crucial for the mutual 
action in combination therapy where TSC may 
interfere with the labile mitochondrial iron 
metabolism through an iron-depleting action or may 
have other more complex effects through a specific 
accumulation.  




The mechanism of cytotoxicity in PDT and TSC 
treatment may rely on the formation of ROS. With this 
in mind, the observed co-localization in mitochondria 
is a desirable feature. Singlet oxygen generation is 
considered to be the main factor that is responsible for 
cellular damage in PDT. Iron chelators may at least 
indirectly participate in the formation of ROS. On the 
other hand, DFO, due to its hexadentate complex 
with Fe(III), is unable to participate in a Fenton 
reaction and in the generation of ROS [33,34]. 
Moreover, at high concentrations, DFO is known 
for its anti-oxidant potency [35]. This feature is in 
agreement with our results, which are shown in Table 
1. To evaluate this hypothesis, we designed an 
experiment to measure the singlet oxygen yield after 
combination therapy in DMEM solutions. Our results 
confirmed that the only PS is responsible for 1O2 
generation during PDT-TSC treatment (Figure A). 
Solutions of either MS168 or Dp44mT alone did not 
generate 1O2 after irradiation. In contrast, irradiated 
PS solutions and mixtures of PS-TSC revealed 
enhanced fluorescence, which clearly indicated 1O2 
generation. In this regard, the 
additional ROS effects of TSC may, 
through different species, influence 
the overall homeostasis of the cell.  
The possible effects of ROS 
generation may be different types of 
cellular damage including lipid 
peroxidation. In further experiments, 
we checked the influence of the 
investigated combinations (TSC+PS) 
on the oxidation processes in a cell 
(Figure B). At all of the 
concentrations, the signals of the 
combination therapy were stronger 
than those of chelators. In general, 
some differences between the two PSs 
– chlorin c and Foscan – were 
observed. For chlorin c, which is a 
less potent PS, a stronger 
malondialdehyde (MDA) signal was 
observed in all of the combinations 
with both TSCs. Foscan, however, has 
a stronger cytotoxic effect (compare 
Table S1 in Supporting Information). 
In this case, its simultaneous 
application with TSCs resulted in a 
stronger lipid peroxidation only at 
lower concentrations. High concen-
trations gave a comparable or even 
lower signal of MDA in the 
Foscan-TSCs due to the overkill effect.  
ROS-degrading proteins are 
other important elements of the total 
antioxidative potential of the cells. As 
was already mentioned, the level of 
MnSOD and CAT may be increased 
after chemotherapy. This is a natural 
mechanism of defense against 
elevated oxidative damage in cells. 
The MnSOD in mitochondria can 
dismutate the O2•- radical into H2O2. 
Then the hydrogen peroxide level is 
regulated by CAT in cytosol. During 
the induced oxidative stress, those 
 
 
Fig. 2. Cellular localization of TSCs; MS168 (a), Dp44mT (b), 3-AP (c) and PSs; chlorin c (d), Foscan (e) in the 
HCT116 cell line. First panel – fluorescence of the investigated compounds alone, middle panel - colocalization 
with mitochondria marker (MitoTracker® Orange for TSC’s and Green for PS’s), last panel - merge. Scale bar 
represents 50 μm. 




enzymes and particularly catalase potency may affect 
the cell survival. The addition of 2-methoxyestradiol, 
which is an MnSOD inhibitor, has been reported to 
improve PDT [25]. In this regard, we hypothesized 
that influencing the overall antioxidative potential of 
the cell may change its vulnerability to therapy. To 
verify this assumption we estimated the expression of 
MnSOD and CAT in response to the investigated 
therapies. As is shown in Figure C, the addition of a 
neocuproine (NCP) ROS scavenger and a chelating 
agent resulted in lowering the expression of genes in 
cancer cells. Foscan increased the expression of both 
genes while chlorin c amplified the level of CAT but 
the MnSOD to a lesser degree. Both chelators strongly 
increased the gene levels, although in a different 
manner. Dp44mT affected the expression of CAT to a 
higher degree than MnSOD. The overall expression of 
genes in the Dp44mT-treated cells was also 
considerably higher. This was in agreement with the 
combination indexes that suggested a stronger 
synergy for this thiosemicarbazone. In all cases, the 
level of ROS-degrading proteins decreased with the 
addition of neocuproine. Noticeably, the combination 
of Dp44mT with Foscan (the strongest synergy) 
caused a lower expression of CAT than any of those 
drugs alone. This effect was also confirmed with the 
addition of NCP. Thus the combination of two drugs 
inducing the redox damage in the cell may results in 
breaking down the antioxidative 
potential of the cell. Iron chelators 
acting through Haber-Weiss and 
Fenton reactions stimulate the cell 
machinery to reduce the elevated 
ROS concentration. Similar effect is 
observed in PS although in smaller 
extent. Increased production of 
oxygen radicals in mitochondria 
results in correspondingly higher 
concentration of H2O2, which causes 
upregulation of CAT to maintain the 
equilibrium. However higher level 
of H2O2 may also facilitate the 
Fenton reaction generating more 
ROS and leading to the cell death. 
Thus lowering the CAT expression 
may increase effectivity of TSC 
therapy [36]. On the other hand 
higher CAT activity produce more 
oxygen which may enhance the PDT 
process as recently reported by Min 
et al. [37]. The exact mechanism of 
CAT downregulation is still not well 
understood, however it can be 
hypothesized that interaction with 
vital metal cations may play a role as 
reported elsewhere [38]. 
Conclusions 
In conclusion, we have shown that the 
co-application of the tested TSCs in xenobiotic-chlorin 
mediated PDT can exert a synergistic effect that is 
apparently due to its engagement in the labile 
mitochondrial iron metabolism and the formation of 
ROS. The synergistic effect is limited to only 
redox-active chelators, as the mobilization does not 
change the PS concentration. Thiosemicarbazones 
accumulate in mitochondria and by redox-active 
complexes generate ROS, whose are substrates for 
MnSOD/CAT enzymes. Combination therapy lead to 
decrease overall cell antioxidative potency by 
downregulation of CAT. The strong interaction 
between Dp44mT and Foscan can be explained on 
this basis. The investigated strategy can be a valuable 
option for increasing the efficiency of PDTs, e.g. for 
therapies that use Foscan, which is an approved PDT 
drug. As described above there is strong interest in 
enhanced photodynamic therapy by addition of 
adjuvant drugs. According to the mechanistic 
consideration the chelation of iron seems to be 
effective way. However the literature reports do not 
fully support such hypothesis. With this in mind our 
results help to understand the baseline mechanism 
beneath photodynamic – adjuvant interactions. 
 
Figure A . Fluorescence response of the Singlet Oxygen Sensor Green reagent to the 1O2 that was generated 
during the irradiation of DMEM solutions containing the investigated PSs and TSCs as well as their combinations. 
The duration of the irradiation that was applied corresponds to a light dose 4-32 J/cm2. 
 




Photodynamic therapy still growing and is 
intensively investigated. Until now different PSs are 
available as endogenic PpIX and chlorin derivatives. 
Iron chelators are another extensively growing group 
of anticancer agents with two drugs currently under 
the clinical trials 3-AP and DpC analog of Dp44mT 
(NCT02688101). With this in mind presented results 
may have particular importance for design clinical 
experiments as different drugs require specific 
approach to obtain positive results.  
Experimental section 
Cell lines 
The human colon cancer cell line HCT116 was 
obtained from ATCC. The cells were grown as 
monolayer cultures in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 12% (HCT116) 
Fetal Bovine Serum (Sigma) and standard antibiotics 
in 75 cm2 flasks (Nunc). Cells were cultured under 
standard conditions at 37°C in a humidified 
atmosphere at 5% CO2 and 37°C and were passaged 
every 3-4 days as required.  
Cellular localization  
The cells were seeded onto glass slides at a 
density of 3·105 cells/slide and incubated at 37°C for 
24 h. Then, the medium was removed and solutions of 
Dp44mT (15 nM), MS168 (15 nM), 3-AP (1.67 μM) and 
PS (2.5 μM) were added. The next day, the cells 
washed with PBS after which MitoTracker® Orange 
(100 nM, 30 min incubation, Molecular Probes) or 
MitoTracker® Green (100 nM, 30 min incubation, 
Molecular Probes) were added. After staining with 
organelle markers, the cells were washed with PBS 
and fixed by 3.7 % paraformaldehyde for 10 minutes. 
Intracellular localization was observed using an 
Olympus Fluoview FV1000 confocal laser scanning 
system equipped with an Olympus IX81 inverted 
microscope (Olympus, Poland). TSCs were excited 
using the laser 405 nm line, MitoTracker Green was 
excited using the argon-ion laser 488 nm line, 
photosensitizers and MitoTracker Orange by the 
helium-neon laser 543 nm line. The fluorescence of 
TSCs, MitoTracker Green, PS and MitoTracker 
Orange were monitored using an emission filters: 461; 
519; 615 and 576 nm, respectively. Image acquisition 
was performed using a 60x oil immersion objective 
lens. The analysis and processing of images were 
performed using an ImageJ 1.41 (Wayne Rasband, 
National Institutes of Health, USA). 
 
Figure B. Lipid peroxidation of the HCT116 cell line after incubation with TSCs, PSs and their combinations. Results are shown as the mean ± SD of three independent 
measurements. Data were analyzed using one-way ANOVA with Bonferroni’s post-hoc test: *p<0.05, **p<0.01, ***p<0.001 as compared to the irradiated control (untreated) 
group. 





Figure C. mRNA expression of MnSOD and CAT in the HCT116 cell line after incubation with TSCs, PSs and their combinations. Results are shown as the mean ± SD of three 
independent measurements. Data were analyzed using the Student’s t-test: *p<0.05, **p<0.01, ***p<0.001 as compared to the irradiated control (untreated) group. 
 
Generation of singlet oxygen 
In order to detect singlet oxygen (1O2) in 
irradiated solutions that contained various 
combinations of the investigated compounds, we 
used Singlet Oxygen Sensor Green (SOSG) 
(Invitrogen). After reaction with 1O2, this selective 
reagent produces fluorescent SOSG endoperoxides 
that after excitation at λ = 488 nm emit a strong green 
fluorescence with a maximum at λ = 532 nm. The 
stock solution of the investigated compounds was 
diluted in DMEM to a final concentration of 10 μM. 
Irradiation was performed in a black 96-well plate 
using an LED light source (Thorlabs, λ = 660 nm) for 
various time intervals. In order to a homogeneous 
illumination of the samples only four wells were 
irradiated in each cycle. The stock solution (in MeOH) 
was added to each well in a final concentration of 10 
μM prior to the SOSG. The fluorescent spectra were 
measured using spectrofluorimeter Hitachi F-7000 
before and after each irradiation period. 
Lipid peroxidation 
The levels of the lipid peroxidation products 
were measured using a modified method of 
Thiobarbituric Acid Reactive Substances (TBARS). 
The cells were seeded in 3 cm Petri dishes (Nunc) at a 
density of 3·105 cells/dish and incubated at 37°C. 
After 24 h, solutions of TSCs and PSs were prepared at 
concentrations of 0.05, 0.75, 1.5, 3, 10 µM and were 




added. The next day, the solution was removed and 
the cells were washed with PBS after which 1 mL of 
DMEM (without phenol red and without FBS) was 
added. The cells were irradiated with a light dose 12 
J/cm2 at wavelength of 660 nm and then incubated at 
37°C. After 3 h, the cells were washed with PBS and 
trypsinized with 0.05% Trypsin-EDTA solution 
(Sigma), then centrifuged for 2 min at 14,000 rpm. The 
cells were suspended in PBS, and then 15 % 
trichloroacetic acid (Sigma) in 0.25 M HCl and 0.37 % 
thiobarbituric acid (Sigma) in 0.25 M HCl were added. 
All of the samples were incubated at 90°C for 20 
minutes, then quick chilled on ice for 5 minutes and 
centrifuged for 5 min at 5,000 rpm. The absorbance of 
supernatant was measured using a multi-plate reader 
(Synergy 4, Bio Tek) at 532 nm. The concentration of 
the final product of lipid peroxidation, 
malondialdehyde (MDA) was calculated using a 
molar extinction coefficient of 156 mM-1cm-1. The 
experiments were performed three times. 
Oxidative stress mRNA expression of MnSOD 
and CAT 
The cells were seeded in 3 cm Petri dishes (Nunc) 
at a density 0.5·106 cells and incubated overnight. 
Then, the medium was removed and solutions of 
Dp44mT (25 nM), MS168 (25 nM) and PS (0.5 μM) 
were added. For quenching ROS, Neocuproine (NCP) 
at a concentration of 25 μM was applied. The next 
day, the cells were irradiated with a light dose of 12 
J/cm2 at a wavelength of 660 nm and then incubated 
at 37°C. After 6h, total RNA was isolated from the 
cells using TRIzol Reagent (Ambion) according to the 
manufacturer’s instructions. cDNA synthesis was 
performed with 5 μg of total RNA using a GoScript ™ 
Reverse Transcriptase kit (Promega) and Oligo(dT)23 
Primers (Sigma). The relative mRNA levels of the 
MnSOD and CAT genes in the TSC-PS-PDT-treated 
cells were determined in comparison with the levels 
of the untreated controls without PDT. Real-Time 
PCR was performed using a CTX96 Touch™ 
Real-Time PCR Detection System (Biorad) at a 
reaction volume of 20 μL. The reaction consisted of 
SYBR Green Mix (Biorad), primers pair mix (0.5 μM 
each) and 1 μL cDNA. All of the primer pair 
sequences were purchased from Sigma-Aldrich and 
are listed in Table S2. The experiment was set up 
under the following conditions: initial denaturation at 
95°C for 20 sec; followed by 40 denaturation cycles at 
95°C, 10 sec; annealing (primer-specific temperature 
for 20 sec) and extension at 72°C for 30 sec. Data was 
analyzed based on a comparison of the expression of 
the target genes to a reference GADPH gene using the 
of 2-ΔΔCT method.  
Statistical analysis 
All of the data are presented as mean values and 
standard deviations (SD). Statistical differences in the 
expression of the genes were calculated using the 
Student’s t-test. Statistical analysis of lipid 
peroxidation was performed using one-way ANOVA 
with a Bonferroni post-hoc test (comparisons of 
multiple groups against the control). A p-value of 0.05 
or less was considered to be statistically significant. 
GraphPad Prism v.5.0 software (GraphPad Software, 
USA) was used for statistical. CI indexes with error 
values were calculated in the CompuSyn software. 
Supplementary Material  
Supplementary tables.  
http://www.jcancer.org/v08p1979s1.pdf  
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